SG10201909199PA - Method for treating cancer - Google Patents

Method for treating cancer

Info

Publication number
SG10201909199PA
SG10201909199PA SG10201909199PA SG10201909199PA SG 10201909199P A SG10201909199P A SG 10201909199PA SG 10201909199P A SG10201909199P A SG 10201909199PA SG 10201909199P A SG10201909199P A SG 10201909199PA
Authority
SG
Singapore
Prior art keywords
treating cancer
inhibitor
ezh2
bstract
present disclosure
Prior art date
Application number
Inventor
Heike Keilhack
Sarah K Knutson
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of SG10201909199PA publication Critical patent/SG10201909199PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A BSTRACT METHOD FOR TREATING CANCER The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s). (no figure)
SG10201909199P 2015-08-24 2016-08-24 Method for treating cancer SG10201909199PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562209304P 2015-08-24 2015-08-24

Publications (1)

Publication Number Publication Date
SG10201909199PA true SG10201909199PA (en) 2019-11-28

Family

ID=58100964

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201909199P SG10201909199PA (en) 2015-08-24 2016-08-24 Method for treating cancer

Country Status (12)

Country Link
US (4) US10493076B2 (en)
EP (1) EP3341080A4 (en)
JP (1) JP2018525414A (en)
KR (1) KR20180042356A (en)
CN (1) CN108025191A (en)
AU (2) AU2016312514A1 (en)
CA (1) CA2996412A1 (en)
EA (1) EA201890567A1 (en)
IL (2) IL307260A (en)
MX (1) MX2018002344A (en)
SG (1) SG10201909199PA (en)
WO (1) WO2017035234A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013024907A2 (en) 2011-03-28 2016-12-20 Mei Pharma Inc compound, pharmaceutical composition, method for treating, preventing or attenuating one or more symptoms of a pi3k-mediated disorder, disease or condition in a subject, method for modulating pi3k enzymatic activity
EA201890567A1 (en) * 2015-08-24 2018-08-31 Эпизайм, Инк. CANCER TREATMENT METHOD
CN114533880B (en) * 2015-09-25 2023-08-22 Epizyme股份有限公司 Methods of treating MRTO/SCCOHT with EZH2 inhibitors
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc Ezh2 inhibitors for treating cancer
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
KR20200009088A (en) 2017-05-23 2020-01-29 메이 파마, 아이엔씨. Combination therapy
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
JP2020531414A (en) 2017-08-14 2020-11-05 エムイーアイ ファーマ，インク． Combination therapy
JP7399079B2 (en) 2017-09-05 2023-12-15 エピザイム，インコーポレイティド Combination therapy to treat cancer
MX2021001606A (en) * 2018-08-14 2021-04-19 Mei Pharma Inc Treatment of b cell malignancies.

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2005000332A2 (en) 2003-06-27 2005-01-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20110064664A1 (en) 2007-10-08 2011-03-17 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
ES2534804T3 (en) 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
US8637509B2 (en) 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
JP5864545B2 (en) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Indole
US9982304B2 (en) 2010-09-03 2018-05-29 The Johns Hopkins University ARID1A and PPP2R1A mutations in cancer
KR102061353B1 (en) 2010-09-10 2020-01-02 에피자임, 인코포레이티드 Inhibitors of human ezh2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
ES2607064T3 (en) 2010-12-01 2017-03-29 Glaxosmithkline Llc Indoles
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2012138783A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
JO3438B1 (en) 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
TW201733984A (en) 2011-04-13 2017-10-01 雅酶股份有限公司 Substituted benzene compounds
ES2655642T3 (en) 2011-05-16 2018-02-21 Ulrike Nuber Novel cancer therapies and methods
ES2624986T3 (en) 2011-09-13 2017-07-18 Glaxosmithkline Llc Azaindazoles
RU2014117632A (en) 2011-09-30 2015-11-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи METHODS FOR TREATING A MALIGNANT TUMOR
WO2013059944A1 (en) 2011-10-28 2013-05-02 British Columbia Cancer Agency Branch Epigenetic regulators and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
TR201904660T4 (en) * 2012-03-12 2019-05-21 Epizyme Inc Human EZH2 inhibitors and methods of use.
US9932317B2 (en) 2012-03-19 2018-04-03 Imperial Innovations Limited Quinazoline compounds and their use in therapy
ES2745016T3 (en) 2012-04-13 2020-02-27 Epizyme Inc N - ((4,6-Dimethyl-2-oxo-L, 2-dihydropyridin-3-yl) methyl) -5- (ethyl (tetrahydro-2H-pyran-4-yl) amino) -4-methyl hydrobromide -4 '- (morpholinomethyl) - [L, 1'-biphenyl] -3-carboxamide for use in the treatment of a cell proliferative disorder of the hematological system
US10301290B2 (en) 2012-04-13 2019-05-28 Epizyme, Inc. Combination therapy for treating cancer
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
EP3628662A1 (en) 2012-10-15 2020-04-01 Epizyme, Inc. Substituted benzene compounds
BR112015008447A2 (en) 2012-10-15 2017-07-04 Epizyme Inc methods to treat cancer
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9895390B2 (en) 2012-12-10 2018-02-20 Children's Medical Center Corporation Methods and assays for combination treatment of cancer
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
PL2953941T3 (en) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014176047A1 (en) 2013-04-25 2014-10-30 Novartis Ag Markers for ezh2 inhibitors
EP2991980B1 (en) 2013-04-30 2019-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
CA2914414A1 (en) 2013-06-06 2014-12-11 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
CA2917463A1 (en) 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
PE20161273A1 (en) 2013-10-16 2016-12-18 Epizyme Inc SALINE FORM OF HYDROCHLORIDE FOR EZH2 INHIBITION
US20160228447A1 (en) 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
CN105873592B (en) 2013-12-06 2023-01-31 Epizyme股份有限公司 Combination therapy for the treatment of cancer
US20160326596A1 (en) 2013-12-31 2016-11-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function
WO2015128837A1 (en) 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
US20170015666A1 (en) 2014-03-07 2017-01-19 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
CN113620958A (en) 2014-03-19 2021-11-09 无限药品股份有限公司 Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders
CN106999498B (en) 2014-06-17 2021-06-08 Epizyme股份有限公司 EZH2 inhibitors for the treatment of lymphoma
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
BR112016029911A2 (en) 2014-06-19 2017-10-24 Memorial Sloan Kettering Cancer Center biomarkers for response to ezh2 inhibitors
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
KR20170045748A (en) 2014-09-05 2017-04-27 아르퀼 인코포레이티드 Compositions and methods for treating proliferation disorders
CA2963149A1 (en) 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
DK3220916T3 (en) 2014-11-17 2023-06-26 Epizyme Inc METHOD FOR TREATMENT OF CANCER WITH N-((4,6-DIMETHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)-5-(ETHYL(TETRAHYDRO-2H-PYRAN-4-YL)AMINO) -4-METHYL-4'-(MORPHOLINOMETHYL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE
MX2017013142A (en) 2015-04-20 2019-03-28 Epizyme Inc Combination therapy for treating cancer.
JP6890097B2 (en) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド EZH2 inhibitor for treating lymphoma
EA201890567A1 (en) * 2015-08-24 2018-08-31 Эпизайм, Инк. CANCER TREATMENT METHOD
CN114533880B (en) 2015-09-25 2023-08-22 Epizyme股份有限公司 Methods of treating MRTO/SCCOHT with EZH2 inhibitors
CA3000983A1 (en) 2015-10-06 2017-04-13 The Regents Of The University Of Colorado, A Body Corporate Method of treating medulloblastoma with an ezh2 inhibitor
JP2018532761A (en) 2015-11-06 2018-11-08 エピザイム，インコーポレイティド Pediatric administration for the treatment of cancer with EZH2 inhibitors
CA3007492A1 (en) 2015-12-07 2017-06-15 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
JP2019508406A (en) 2016-02-08 2019-03-28 エピザイム，インコーポレイティド How to treat cancer
EP3469099A1 (en) 2016-06-08 2019-04-17 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
EP3576729A4 (en) 2017-02-02 2021-04-14 Epizyme, Inc. Cancer treatment modalities

Also Published As

Publication number Publication date
US20200155561A1 (en) 2020-05-21
US20240024331A1 (en) 2024-01-25
CA2996412A1 (en) 2017-03-02
EA201890567A1 (en) 2018-08-31
IL257691A (en) 2018-04-30
WO2017035234A1 (en) 2017-03-02
AU2016312514A1 (en) 2018-03-15
MX2018002344A (en) 2018-07-06
US11642349B2 (en) 2023-05-09
US20180235975A1 (en) 2018-08-23
AU2022202118A1 (en) 2022-04-14
US10898490B2 (en) 2021-01-26
JP2018525414A (en) 2018-09-06
IL307260A (en) 2023-11-01
CN108025191A (en) 2018-05-11
EP3341080A4 (en) 2019-03-20
US10493076B2 (en) 2019-12-03
US20210213027A1 (en) 2021-07-15
KR20180042356A (en) 2018-04-25
EP3341080A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
MX2021006734A (en) Method for treating cancer.
SG10201909199PA (en) Method for treating cancer
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2019001125A (en) Macrocycle kinase inhibitors.
MX2016007351A (en) Combination therapy for treating cancer.
WO2016025635A3 (en) Combination therapy for treating cancer
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MX2017013142A (en) Combination therapy for treating cancer.
MX2017004618A (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
EA201692483A1 (en) HYSTON METHYLASE INHIBITORS
WO2016043874A3 (en) Combination therapy for treating cancer
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
EP3538119A4 (en) Compositions and methods for treating skin diseases and maintaining healthy skin
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
MX2016014436A (en) Heterocyclyl-butanamide derivatives.
MX2017003466A (en) Histone demethylase inhibitors.
MX2019013862A (en) Combination therapy.
MX2017013137A (en) Chromene derivatives as phoshoinositide 3-kinases inhibitors.
MX2016009655A (en) Novel methods for treating cancer.
EP3700551A4 (en) Cancer vaccine compositions and methods for using same to treat cancer